carecentrix

Provider Newsflash
December, 2022

FDA Recall – Hospira, Inc. Vancomycin HCL Injection

Purpose of this communication:

- We are writing to inform you that effective immediately the FDA has issued notice of a voluntary nationwide recall by Hospira, Inc., a Pfizer company, of one lot (#33045BA) of Vancomycin Hydrochloride Injection, USP 1.5 g/vial single dose flip top vial, expiration date September 1, 2023, to the user level due to two visible glass particulates observed in a single vial. If administered intravenously, patients may experience adverse events such as local irritation or swelling, vasculitis/phlebitis, antigenic or allergic reactions, and microvascular obstruction including pulmonary embolism.

What do I need to do?

- Please review the following recall notice: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/hospira-inc-issues-voluntary-nationwide-recall-one-lot-vancomycin-hydrochloride-injection-usp?utm_medium=email&utm_source=govdelivery
- Notify impacted patients and facilitate the replacement or resolution of the recall, according to the guidelines issued by the manufacturer in the FDA notification.
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by faxing information to: 919-792-6718 Attn: Quality Department.

Thank you in advance for your cooperation and continued partnership.